BEIJING – Asia is rapidly becoming the location of choice for clinical studies by many leading drug developers, with the number of studies in East Asia already topping 14,000, and Mainland China, Hong Kong, South Korea and Taiwan emerging as popular locations.
BEIJING – Negotiating partnering or joint venture deals can be challenging under any circumstances. In China, the process is exacerbated by cultural differences, mistrust, disparate negotiating styles and, most visibly, disjointed views of compliance requirements.
BEIJING – The secret to the China market, said industry stakeholders during the 2013 BIO Convention in China this week, is to look for and fill unmet medical needs.
HONG KONG – Japan’s biotech stocks have fallen from the precipitous heights they reached through the first half of the year, coming down from a bubble that was driven by a combination of a cheap currency, government stimulus, a new health care policy and a Nobel Prize.
HONG KONG – Authorities in China are working to plug a regulatory hole related to post-market studies for new chemical entities (NCE) and biological drugs.
HONG KONG – With its latest acquisition, China’s Walvax Biotechnology Co. is raising the ante on its investments to $600 million, hoping to leverage its growing size into a profitable pipeline of, among other things, monoclonal antibodies (MAbs).
HONG KONG – 3SBio Inc. has acquired the patents for a new drug to treat renal failure from the Shanghai Institute of Materia Medica (SIMM) as part of its efforts to expand its offerings linked to diseases of the kidney.
HONG KONG – Looking to expand its global footprint, China’s largest biotech, Shanghai Fosun Pharmaceutical Group, has inked a potential $531 million deal with Switzerland’s Sellas Clinicals Holding Ag for two drug candidates. The deal not only gives Fosun cash to continue its focus on drug development, but also allows Sellas to diversify its product offerings and sources of new drugs.
